Abstract
This chapter of CNS Drug Discoveries focuses on the developments in the
insomnia market and the substantial changes beginning to take place.
The insomnia market is a maturing market and we believe the landscape will
change dramatically over the next five years as the market enters a transition
phase and becomes more fragmented. We forecast it will grow to nearly US$6
billion by 2012 driven by a number of factors including the launch of new
formulations, new drug classes, patient dynamics (ageing patient population)
and changes in the way insomnia is treated.
Sleep disorders cover a range of problems, the best known types being
insomnia, sleep apnoea and restless legs syndrome. Insomnia is the most
prevalent sleep disorder and it is estimated to affect over 37 million US
citizens and over 100 million people worldwide with approximately 25% of
elderly people and 15% of the general population suffering from the condition.
Studies suggest that less than 20% of insomniacs seek help and less than 20%
of sufferers are prescribed a medication from their doctor.
Global insomnia market Approximately US$2.4 billion is currently spent on
hypnotics and sedatives in the treatment of insomnia, the 10th largest segment
of CNS drug sales. The global market for insomnia drugs is unevenly
distributed. In 2005, the US insomnia market accounted for 66% of the global
market compared to 24% in Europe and 10% in the rest of world (largely Japan).
This is mainly due to the pricing differential between the European and the US
market.
GABA-A receptor agonists (non-benzodiazepines) continue to remain the
cornerstone for the treatment of both acute and chronic insomnia. However, the
launch of several new products over the next 3 years will help to increase
patient awareness, particularly in the elderly.
| 
View Cart
